LJive.com

Website information and statistics

 

72.34.128.214 (PERJETA-RWC.GENE.COM)

A total of 1 sites are hosted on 72.34.128.214.
Here are the first 5 as they would appear when searched for:

HER2+ Breast Cancer Treatment | PERJETA® (pertuzumab)

perjeta.com

Learn about PERJETA®, a neoadjuvant and metastatic breast cancer treatment for patients with HER2-positive breast cancer. What does PERJETA treat? PERJETA® (pertuzumab) is approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer. PERJETA® (pertuzumab) is approved for use prior to surgery in combination with Herceptin® (trastuzumab) and docetaxel in people with HER2-positive, locally advanced, inflammatory, or early stage (tumor is greater than 2 cm in diameter or node positive) breast cancer. PERJETA should be used as part of a complete treatment regimen for early stage breast cancer. This use of PERJETA is based on an improvement in the percentage of patients whose cancer shrinks or disappears after treatment. Currently, no data have shown whether or not treatment with PERJETA prior to surgery improves survival. • The safety of PERJETA in combination with doxorubicin-containing regimens has not been established • The safety of PERJETA administered for greater than 6 cycles for early-stage breast cancer has not been established. Important Safety Information • PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure) • Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects — If you think you may be pregnant, you should contact your healthcare provider immediately — If you are exposed to PERJETA during pregnancy, or become pregnant while receiving PERJETA or within 7 months following the last dose of PERJETA in combination with Herceptin, you are encouraged to enroll in the MotHER Pregnancy Registry by contacting 1-800-690-6720 or visiting http://www.motherpregnancyregistry.com/ and report PERJETA exposure to Genentech at 1-888-835-2555 • PERJETA should not be used in patients who are allergic to pertuzumab or to any of the ingredients in PERJETA • Other possible serious side effects of PERJETA therapy include: — Infusion-related reactions — Severe allergic reactions (hypersensitivity reactions/anaphylaxis) • PERJETA has only been shown to work in people with HER2-positive breast cancer • The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are: — Diarrhea — Hair loss — Low levels of white blood cells with or without a fever — Nausea — Feeling tired — Rash — Damage to the nerves (numbness, tingling, pain in hands/feet) • The most common side effects of PERJETA when given with Herceptin and docetaxel as part of an early breast cancer regimen before surgery are: — Hair loss — Diarrhea — Nausea — Low levels of white blood cells with or without a fever • The most common side effects of PERJETA when given with Herceptin and docetaxel following 3 cycles of epirubicin, cyclophosphamide, and fluorouracil as part of an early breast cancer regimen before surgery are: — Feeling tired — Hair loss — Diarrhea — Nausea — Vomiting — Low levels of white blood cells with or without a fever • The most common side effects of PERJETA when given with Herceptin, docetaxel, and carboplatin as part of an early breast cancer regimen before surgery are: — Feeling tired — Hair loss — Diarrhea — Nausea — Vomiting — Low levels of white blood cells with or without a fever — Low platelet count — Low levels of red blood cells You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555. Please see additional select Important Safety Information throughout, and the accompanying full Prescribing Information including most serious side effects.


This is our visitors' thoughts about IP 72.34.128.214


  1. return to previous: 72.32.90.115
  2. go to the next: 72.34.254.217

 
You are visiting canonical version of the page.
The original page:
https://ljive.com/ipaddress/72.34.128.214
6